-
Current Immune Checkpoint Inhibitors - Late-Phase Clinical Trials
Immune checkpoint inhibitors continue to revolutionize the current clinical oncology landscape. DRG experts used Oncology Clinical Trial Monitor data to provide an overview of the late-phase immune...
-
CAR T-cell Therapy Pipeline and Forecast Snapshot
CD19-targeted CAR T cells – Kymriah and Yescarta – herald a new era and paradigm shift in cancer treatment. Novartis and Gilead paved way for bringing this cutting-edge technology to patients who...
-
Mapping the Clinical Path in Ulcerative Colitis With Real World Data
Real World Data has the potential to boost brand performance, fine-tune commercial strategy, tease out subtle market nuances, and unlock hidden opportunities. The below infographic utilizes US claims...
-
How Pharma Can Differentiate in the Value-Driven Market
Multiple market disruptions are shaking up the healthcare value chain and underscoring the need for pharma companies demonstrate value in order to differentiate and build relationships with customers...
-
What Does Healthcare Delivery Transformation Mean for Pharma?
The U.S. healthcare delivery model is undergoing dramatic changes, with the PBM “Big 3” all announcing mergers in recent months, and Amazon and other entities looking at ways to disrupt the...
-
Global Market Access: 2017 Key Events and Future Impacts
This live session took place on Tuesday, April 17th 2018. Led by expert analysts from Decision Resource Group’s Global Market Access Insights team, this webinar examines key events from 2017 that...
-
Phase III Epacadostat + Keytruda Trial Failure: How Will it Impact the Oncology Landscape?
Forecasting the likelihood of success of late-phase clinical trials in oncology is complex. Positive efficacy signals observed in early-phase trials are frequently not reproduced in more rigorous,...
-
Biosimilars Insights Infographic
Global Biosimilars Pathways and Clinical Development Activity Since the introduction of the first biosimilar guidelines in 2005, the biosimilars field has continued to evolve. Over fifty biosimilars...
-
The Art of the Oncology Deal
The number of deals in the pharmaceutical space has the tendency to fluctuate, but in recent years there has been a proportional increase in the amount of strategic partnerships, acquisitions, and...
-
The Politics of US Healthcare: Implications of MACRA on Physicians, Bundled Payments, Medicare, & Tech
This live session took place on Thursday, March 8th 2018. With new Health and Human Services Secretary Alex Azar now at the helm, provider Medicare reimbursement changes are looming under the Medicare...
A global consultancy and training agency providing market leading product & portfolio strategy, health economic outcomes research & evidence generation, value communication and training services across the life science industry.
We partner with both the biopharmaceutical and medical technology industry to support commercialization & patient access across a variety of functions including: R&D, commercial strategy, HEOR, market access, new product planning, marketing, data insights & analytics, business development and channel & segment customer engagement.
